FINHUB Insights

DXCM · Q3 FY25 · Jul 1 – Sep 30, 2025

Dexcom Q3 FY25: where the revenue came from and where it went

Dexcom Q3 FY25: revenue $1.2B (+22% year over year). Net profit $0.28B. Largest cohort US $0.9B. The whole income statement as a sankey diagram from the SEC filing.

Period
Jul 1 – Sep 30, 2025
Reported
Oct 30, 2025 10-Q
Sankey diagram of Dexcom's income statement for Q3 FY25: revenue of $1.21 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$1.21B +22% year over year
Gross profit$0.73B 60% margin
Operating profit$0.24B 20% margin
Net profit$0.28B 23% margin

The numbers

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Sep 30, 2025).
ItemValueShare of revenueYear over year
Revenue 1.21 100% +22%
US 0.85 70% +21%
Non US 0.36 30% +22%
Cost of revenue−0.4840%
Gross profit0.7360% margin+1pp
R&D−0.1613%−1pp
SG&A−0.3327%−3pp
Operating profit0.2420% margin+5pp
Tax−0.07
Net profit0.2823%+10pp
Filing on EDGAR More quarters of DXCM

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.